Steven C. Lavender
{ Bio Portrait }

Steven Lavender is an antitrust associate in Axinn’s Washington, DC office. Previously a lead attorney with the FTC, Steve has experience with merger clearance in a variety of industries, including pharmaceuticals and medical devices. Steve has conducted HSR Part II investigations, including drafting second requests, taking investigational hearings, obtaining third-party declarations, and drafting recommendations to the Commission. He has also litigated cases in Federal District Court and FTC Administrative Court, including taking and defending depositions, preparing witnesses for trial, and conducting witness examination at trial.

Steve was a law clerk to the office of former FTC Commissioner Joshua D. Wright. Prior to attending law school, Steve served as a Supply Officer in the United States Navy. He earned his JD from Antonin Scalia Law School at George Mason University, where he was one of ten students whose comments were selected for publication in the George Mason Law Review. He also holds a BA in Economics from Northwestern University.

Professional Activities

  • American Bar Association, Section of Antitrust Law and Young Lawyers Division
  • American Bar Association, Health Law Section
  • American Health Lawyers Association, Antitrust Practice Group - Member


Private Practice

  • Currently represents Shintech Incorporated in a class action alleging a conspiracy to raise prices and restrict output of caustic soda
  • Currently represents Shin-Etsu Chemical Co., Ltd. in its personal jurisdiction challenge in a class action alleging a conspiracy to raise prices and restrict output of caustic soda
  • Represented Tufts Health Plan in its merger with Harvard Pilgrim Health Care


  • Litigated the FTC’s successful challenge to Otto Bock’s acquisition of Freedom Innovations
  • Led investigation of Otto Bock’s consummated acquisition of Freedom Innovations, resulting in the FTC’s administrative challenge
  • Investigated the proposed acquisition of Rite Aid by Walgreens
  • Investigated Teva’s acquisition of Allergan’s generic pharmaceutical business, resulting in a consent decree requiring the divestiture of 79 products
  • Investigated and litigated in federal court Steris’s acquisition of Synergy
  • Investigated Zimmer’s acquisition of Biomet, resulting in a consent decree requiring the divestiture of several orthopedic products
  • Investigated Eli Lilly’s acquisition of Novartis’s animal health division, resulting in a consent decree requiring the divestiture of canine heartworm disease products
  • Investigated Valeant’s acquisition of Precision Dermatology, resulting in the divestiture of branded and generic pharmaceutical products
  • Investigated Novartis’s acquisition of Fougera, resulting in divestitures related to generic pharmaceutical products
  • Participated in the FTC’s study of merger remedies between 2006 and 2012, resulting in the FTC’s 2017 Report

Pro Bono

  • Negotiated a favorable settlement and dismissal of several copyright infringement matters for a pro bono client in the Eastern District of Virginia

Thought Leadership


  • JD, cum laude – George Mason University, Antonin Scalia Law School (2013)
  • BA, Economics – Northwestern University (2004)


  • District of Columbia
  • Virginia
  • US District Court Eastern District of Virginia
  • US District Court Western District of Virginia

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.